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Hepatic steatosis is associated with poor cardiometabolic health, with de novo lipogenesis
(DNL) contributing to hepatic steatosis and subsequent insulin resistance. Hepatic saturated
fatty acids (SFA) may be a marker of DNL and are suggested to be most detrimental
in contributing to insulin resistance. Here, we show in a cross-sectional study design
(ClinicalTrials.gov ID: NCT03211299) that we are able to distinguish the fractions of hepatic
SFA, mono- and polyunsaturated fatty acids in healthy and metabolically compromised
volunteers using proton magnetic resonance spectroscopy (1H-MRS). DNL is positively
associated with SFA fraction and is elevated in patients with non-alcoholic fatty liver and type
2 diabetes. Intriguingly, SFA fraction shows a strong, negative correlation with hepatic insulin
sensitivity. Our results show that the hepatic lipid composition, as determined by our 1H-MRS
methodology, is a measure of DNL and suggest that specifically the SFA fraction may hamper
hepatic insulin sensitivity.
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Non-alcoholic fatty liver (NAFL) is the most common causeof chronic liver disease, with estimated prevalence rates of20–35% in Western countries1. In obese people NAFL
prevalence rates as high as 50–70% have been reported2. NAFL
can progress to steatohepatitis, fibrosis, and cirrhosis, which can
lead to liver failure, and hepatocellular carcinoma3. Moreover,
ectopic fat accumulation in the liver is associated with impair-
ments in cardiometabolic health4,5. In this respect, NAFL has
been shown to be associated with insulin resistance on hepatic
and whole-body level6–9.
However, not all individuals with NAFL will develop insulin
resistance, steatohepatitis or other liver disease, and it is of utmost
clinical importance to understand which factors contribute to a
pathologic fatty liver. It has been suggested that the pathway by
which fat accumulation in the liver occurs may impact the clinical
outcome. It has been shown that high rates of de novo lipogenesis
(DNL) are associated with metabolic risk10–12. In addition, ani-
mal experiments have suggested that the degree of saturation of
the accumulating fatty acids in the liver may impact the metabolic
consequences, with more saturated fatty acids (SFA) leading to
worsened metabolic outcome13. Interestingly, the end product of
de novo synthesis of fatty acids is mainly SFA and therefore, high
rates of DNL may result in a higher proportion of hepatic SFA,
possibly explaining why DNL is associated with poor metabolic
health. These findings stress the importance for a more detailed
characterization of hepatic lipid composition in humans, to
ultimately understand the risk factors for the development of
hepatic insulin resistance and disease.
However, in humans such data is very scarce, mainly due to the
invasiveness of liver biopsy procedures that are needed. There-
fore, only very few studies have determined hepatic fat compo-
sition, and these studies have been performed in patients in which
liver biopsies were justified due to their risk for liver disease.
Generally, these studies showed higher mono-unsaturated fatty
acids (MUFA) fraction at the expense of the poly-unsaturated
fatty acids (PUFA) fraction in people with NAFL compared to
people without NAFL14,15. Earlier MR-based studies already
investigated some parameters that are linked to degree of unsa-
turation16–19, however these do not specifically and robustly
quantify hepatic SFA, MUFA, and PUFA fraction separately.
Here, we develop, validate, and apply a magnetic resonance
(MR) post-processing tool that enables to non-invasively quantify
the fractions of hepatic SFA, MUFA, and PUFA separately, in
healthy and metabolically compromised human volunteers. Using
this methodology, we test the hypothesis that higher rates of DNL
are associated with an increased fraction of SFA in human liver.
We also investigate if populations at higher risk to develop
metabolic complications are characterized by altered hepatic fatty
acid composition, and whether hepatic fatty acid composition is
related to hepatic insulin sensitivity (IS). We show that our 1H-
MRS postprocessing methodology can be used to measure hepatic
fatty acid composition in humans, that hepatic SFA content is
strongly related to rates of DNL, and that specifically the hepatic
SFA fraction is related to hepatic insulin resistance.
Results
Development and validation of hepatic 1H-MRS method. To
allow determination of hepatic fatty acid composition, we
developed a 1H-MRS analysis protocol. To this end, we used
information from 1H high-resolution (HR) NMR spectra from
five different vegetable oils to improve our analysis routine and
used 13C HR NMR to determine the true lipid composition of
these oils. We acquired spectra from these different oils with
proton magnetic resonance spectroscopy (1H-MRS) on our
clinical 3T scanner and calculated average corrections factors to
correct for TE-induced losses in the 1H-MRS spectra. When using
the average corrections factors, the lipid composition as deter-
mined by our clinical protocol showed excellent agreement with
the true lipid composition determined by HR NMR: the intraclass
correlation coefficient (ICC) for SFA, MUFA, and PUFA fraction
was 0.982, 0.970, 0.987, and the CV was 6%, 9%, and 9%,
respectively (Fig. 1).
As it is known that in vivo several factors can influence MR
spectra, the next step was to validate our method in vivo. To this
end, we aimed to validate our 1H-MRS lipid composition
measurement with analysis performed in biopsy material. As it
is ethically difficult to take liver biopsies for this purpose, we
rather performed subcutaneous adipose tissue biopsies, which is
far less invasive. Therefore, we validated our MRS method in vivo
by comparing lipid composition in subcutaneous adipose tissue
acquired by the 1H-MRS technique and by mass spectrometry
analysis in subcutaneous adipose tissue biopsies in eight
participants (Fig. 2). As can be seen in Fig. 2, there was
reasonably good agreement between the two methods. The ICC
for SFA, MUFA, and PUFA fraction was 0.333, 0.146, 0.306 and
the CV was 8%, 7%, 12%, respectively. Thus, lipid composition
determined by 1H-MRS in vivo is in close agreement with lipid
composition measured ex vivo in adipose tissue biopsies. The
final validation step was to apply our protocol in the liver in vivo.
We tested reproducibility in seven healthy individuals (separate
group) with intrahepatic lipid content ranging from 2% to 18%
(Fig. 3). As can be seen in Fig. 3, the ICC for total IHL content,
SFA, MUFA, and PUFA fraction was found to be 0.997, 0.562,
0.756, 0.557 and the CV was 4%, 4%, 3%, and 12%, respectively.
These results indicate high reproducibility for determining in vivo
hepatic lipid composition using our developed approach.
In addition, we compared hepatic lipid composition by our
MRS method to plasma VLDL-triglyceride (VLDL-TG) composi-
tion acquired by mass spectrometry analysis in 17 participants
(Fig. 4). As can be seen in Fig. 4, especially the SFA fraction
showed a strong correlation with hepatic SFA% (Pearson r= 0.80,
p < 0.001).
Higher hepatic SFA is associated with increased DNL. DNL is
an important factor in the development of fatty liver20. We
hypothesized that DNL would specifically lead to the accumula-
tion of SFA, as palmitate is the main product of DNL. Therefore,
we determined DNL by deuterated water in overweight and obese
participants with a wide range of liver fat content (n= 16,
0.9–38.4%) and related it to the hepatic fatty acid composition
determined by our MRS protocol in the same volunteers. DNL
was not associated with total liver fat content (Fig. 5a). Interest-
ingly, however, DNL correlated positively with the hepatic SFA
fraction (Pearson r= 0.52, p= 0.047; Fig. 5b). Furthermore, we
found a strong negative correlation between DNL and hepatic
MUFA fraction (Pearson r=−0.71, p= 0.003; Fig. 5c). In addi-
tion, DNL was negatively correlated with MUFA/SFA ratio
(Pearson r=−0.64, p= 0.010; Fig. 5e). No association was found
between DNL and PUFA fraction (Fig. 5d). Of note, SFA fraction
in plasma VLDL-TG did not correlate with DNL (Pearson r=
0.27, p= 0.308). These results suggest that (1) higher rates of
DNL lead to altered saturation of hepatic lipids and (2) that our
non-invasive method can be used as a measure of the degree of
DNL, directly in the liver.
Hepatic SFA fraction is of clinical relevance in humans. To
investigate if hepatic lipid composition may also have clinical
relevance, we compared hepatic lipid composition in volunteers
with a range in metabolic complications. We subdivided the
volunteers in whom we demonstrated the relationship between
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DNL and hepatic SFA, into participants with NAFL (liver fat
content >5%, n= 15) and control participants (liver fat content
<5%, n= 7); volunteers with NAFL are known to be at increased
risk to develop type 2 diabetes and other cardiometabolic dis-
orders6–8. In addition, we measured hepatic lipid fractions and
hepatic IS in a group of patients with type 2 diabetes (n= 9) and
furthermore, determined hepatic lipid fractions in glycogen sto-
rage disease type 1a (GSD1a) patients (n= 7), known to have
elevated rates of DNL. This inborn error of metabolism is caused
by a defect in glucose-6-phosphatase, which hampers the
final step in gluconeogenesis and glycogenolysis in liver and
kidney, and, as a consequence, favors the shift of glucose-6-
phosphate towards DNL and hepatic steatosis21. Control and
NAFL participants and patients with type 2 diabetes were com-
parable in age and BMI. All subject characteristics are summar-
ized in Table 1.
Hepatic SFA fraction was higher in NAFL individuals (42.9 ±
0.8%, ANOVA, p= 0.022, mean ± SEM; Fig. 6b) and in type 2
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Fig. 1 Validation of 1H-MRS method in oil phantoms. a Lipid spectra acquired from five different oil phantoms (arachis, olive, rice, safflower, and sunflower
oil) showing the different lipid proton peaks and their position. b Lipid spectrum and fit of arachis oil. Correlations between c SFA, d MUFA, e PUFA
measured at 3T with 1H-MRS and measured with high-resolution 13C-NMR spectroscopy. The intraclass correlation coefficient (ICC) is shown in the
respective plots (Intraclass correlation).
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diabetes patients (43.9 ± 1.7%, ANOVA, p= 0.016; Fig. 6b)
compared to controls (35.5 ± 3.1%). Hepatic MUFA and PUFA
fractions did not significantly differ between these groups (Fig. 6c
and d). No significant associations were found between hepatic
fat content and any of the FA fractions in healthy participants
with and without NAFL. Therefore, these data suggest that
specifically the SFA fraction is elevated in metabolically
compromised volunteers.
To further confirm that DNL and SFA fraction may be causally
related, and to further investigate the clinical relevance of SFA, we
determined SFA fraction in a specific group of patients, known to
have elevated rates of DNL, i.e. patients with GSD1a (n= 7). In
these patients, SFA fraction (49.5 ± 2.0%) was markedly higher
compared to NAFL participants (42.9 ± 0.8%, ANOVA, p=
0.034; Fig. 6b) and controls (35.5 ± 3.1%, ANOVA, p < 0.001;
Fig. 6b). The MUFA fraction in these patients was reduced
compared to controls (33.2 ± 1.1% vs. 45.2 ± 4.2%, ANOVA, p=
0.006; Fig. 6c). These results further confirm that the fraction of
hepatic SFA and MUFA reflect the rate of DNL and can be used
as a non-invasive measure to characterize hepatic metabolism in
clinical patients in more detail.
Higher hepatic SFA is associated with reduced hepatic IS. Our
results so far suggest that specifically the saturated fat fraction is
elevated in patients and individuals with an enhanced metabolic
risk. These data are consistent with findings in animal studies,
where it was found that specifically hepatic SFA is of importance in
relation to insulin resistance13. We therefore investigated the rela-
tionship between hepatic lipid composition and hepatic IS using the
golden-standard two-step hyperinsulinemic euglycemic clamp.
Hepatic IS was found to be 40% lower in patients with type 2
diabetes compared to controls (EGP suppression controls: 74.2 ±
7.0% and T2D: 41.6 ± 4.1%, ANOVA, p= 0.002; Fig. 7f), with
intermediate values in NAFL (EGP suppression 56.9 ± 4.9%;
Fig. 7f). The hepatic SFA fraction was strongly and negatively
associated with hepatic IS (Spearman r=−0.55, p= 0.002; Fig. 7b),
whereas correlation with hepatic MUFA fraction was weaker
(Spearman r= 0.39, p= 0.034; Fig. 7c) and PUFA fraction and total
hepatic fat content did not correlate with hepatic IS (Fig. 7a, d).
Furthermore, the MUFA/SFA ratio was positively associated with
hepatic IS (Spearman r= 0.51, p= 0.005; Fig. 7e). These results
suggest that specifically the SFA fraction in the liver negatively
contributes to hepatic IS, rather than the total amount of hepatic fat.
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Fig. 2 Validation of 1H-MRS method in subcutaneous adipose tissue. a T2 weighted Turbo spin echo MR image showing the voxel position located on
adipose tissue and its corresponding lipid spectrum together with the fitted spectrum. The relationships between subcutaneous adipose tissue measured at
3T and adipose lipid composition determined through biopsy for the different lipid fractions: b SFA, cMUFA, and d PUFA (n= 8). The intraclass correlation
coefficient (ICC) is shown in the respective plots (Intraclass correlation).
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Discussion
The relation of hepatic lipid composition to cardiometabolic
health and specifically insulin resistance has not been investigated
in humans. Due to the invasive procedures necessary and due to
challenges accompanying the use of non-invasive methods, such
as 1H-MRS, determination of hepatic lipid composition is
hampered. Here, we developed, validated, and applied 1H-MRS
methodology that enabled us to non-invasively quantify the
fractions of hepatic SFA, MUFA, and PUFA separately. We
showed that DNL was positively related to the hepatic SFA
fraction and negatively to the MUFA fraction in overweight/obese
participants, suggesting that high rates of DNL modify fatty acid
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Fig. 3 Validation of 1H-MRS method by testing reproducibility in vivo. a T2 weighted Turbo spin echo MR image showing the voxel position located on
liver and its corresponding lipid spectrum together with the fitted spectrum. Scatter plots showing the reproducibility of b total liver fat content and c SFA
fraction, d MUFA fraction, and e PUFA fraction (n= 7). Reproducibility was tested by performing two repeated measurements. The intraclass correlation
coefficient (ICC) is shown in the respective plots (Intraclass correlation).
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composition. We confirmed this association between DNL and
hepatic SFA fraction by showing increased hepatic SFA fraction
in GSD1a patients, a genetic model of increased DNL. Further-
more, we showed that the hepatic SFA fraction is elevated in
NAFL and type 2 diabetes patients and related to hepatic insulin
resistance. These results show that our 1H-MRS protocol can be
used to determine hepatic fat composition in humans and that
particularly the SFA fraction can be seen as a non-invasive
measure of DNL, directly measured in the liver. Furthermore, our
results indicate that hepatic lipid composition may be a clinically
important feature of hepatic fat accumulation.
Previously, a few studies have used similar approaches using
1H-MRS for hepatic lipid profiling, but none of these studies have
reported SFA, MUFA, and PUFA fractions separately16–19. Even
more so, in case of changes in MUFA/PUFA ratios, the calcula-
tion of the saturation index by using the methine resonance can
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lead to a misinterpretation of the lipid composition. We here
show that by acquiring high-quality liver spectra and by applying
a sophisticated post-processing method for these spectra, it is
possible to differentiate between the hepatic SFA, MUFA, and
PUFA fractions in vivo in subjects with and without NAFL.
Implementation of this methodology in future studies makes it
possible to further explore the importance of hepatic fat
composition in metabolic health and the factors that could
modulate fatty acid composition.
High rates of DNL may change hepatic lipid composition. The
end product of the lipogenic pathway is palmitate (C16:0), which
in turn can undergo elongation to stearate (C18:0) and desa-
turation by Stearoyl-CoA desaturase-1 (SCD1) to the MUFAs
palmitoleate (C16:1 n-7) and oleate (C18:1 n-9). Previously, it has
Table 1 Subject characteristics of control and NAFL participants, patients with T2D and GSD1a.
Control (n= 7) NAFL (n= 15) T2D (n= 9) GSD1a (n= 7)
Age (years) 59 ± 6.8 58 ± 7.1 65 ± 4.5 37 ± 12.3a–c
BMI (kg/m2) 29.1 ± 2.3 30.7 ± 3.1 29.4 ± 4.2 27.5 ± 3.2
Sex (f/m) 6/1 7/8 2/7 5/2
Body fat (%) 42.1 ± 8.1 42.1 ± 7.8 34.1 ± 5.8 –
Plasma glucose (mmol/L) 5.2 ± 0.4 5.6 ± 0.5 7.5 ± 1.1a, b 3.9 ± 0.8a–c
Plasma insulin (pmol/L) 35.2 ± 8.1 89.8 ± 40.4a 72.8 ± 58.3 13.8 ± 5.0b, c
Plasma NEFA (mmol/L) 667 ± 58 623 ± 141 566 ± 211 876 ± 421
Plasma TG (mmol/L) 1.5 ± 0.8 2.6 ± 1.2 1.6 ± 0.5 5.0 ± 1.5a–c
ALT (U/L) 22 ± 4.1 35 ± 14.4 27 ± 11.4 18 ± 4.9b
AST (U/L) 22 ± 3.7 28 ± 6.3 23 ± 5.9 34 ± 9.3 a, c
Intrahepatic fat content (% weight/weight) 2.2 ± 1.3 14.4 ± 10.4a 6.9 ± 5.2 16.5 ± 18.9a
Data are presented as mean ± SD. Overweight/obese controls without NAFL (controls, n= 7), overweight/obese with NAFL (NAFL, n= 15), patients with type 2 diabetes (T2D, n= 9), and GSD type 1a
(GSD1a, n= 7). Age was significantly lower in GSD1a compared to control (p= 2.5 × 10−5), NAFL (p= 3.0 × 10−6), and T2D (p= 1.47 × 10−7). Plasma glucose was significantly lower in GSD1a compared
to control (p= 0.011), NAFL (p= 5.6 × 10−5) and T2D (p= 1.44 × 10−10), and was significantly higher in T2D compared to control (p= 4.0 × 10−6) and NAFL (p= 6.0 × 10−6). Plasma insulin was
significantly lower in GSD1a compared to NAFL (p= 3.4 × 10−5) and T2D (p= 0.006), and was significantly higher in NAFL compared to control (p= 0.048). Plasma TG was significantly higher in
GSD1a compared to control (p= 3.0 × 10−6), NAFL (p= 1.33 × 10−4), and T2D (p= 2.0 × 10−6). ALT was significantly higher in NAFL compared to GSD1a (p= 0.011). AST was significantly higher in
GSD1a compared to control (p= 0.006) and T2D (p= 0.017). Intrahepatic fat content was significantly higher in NAFL compared to control (p= 0.002) and GSD1a compared to control (p= 0.027).
Bonferroni correction was used for post-hoc analyses.
aSignificantly different from control.
bSignificantly different from NAFL.
cSignificantly different from T2D (Kruskal–Wallis, p < 0.05 for plasma insulin, plasma NEFA, ALT and intrahepatic fat content, and one-way ANOVA, p < 0.05 for all other parameters).
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Fig. 6 Liver fat content and composition in groups with different metabolic disorders. Comparisons between overweight/obese controls without NAFL
(controls, n= 7 for total liver fat content, n= 6 for liver fat composition), overweight/obese with NAFL (NAFL, n= 15), patients with type 2 diabetes (T2D,
n= 9) and GSD type 1a (GSD1a, n= 7). a Total liver fat content in control, NAFL, T2D, and GSD1a. Total liver fat content was significantly higher in the
NAFL group compared to the control group (p= 0.002) and in the GSD1a group compared to the control group (p= 0.027). b SFA fraction in control,
NAFL, T2D, and GSD1a. SFA fraction was significantly higher in the GSD1a group compared to the control group (p= 7.3 × 10−5) and NAFL group (p=
0.034), significantly higher in the T2D group compared to the control group (p= 0.016), and significantly higher in the NAFL group compared to the
control group (p= 0.022). cMUFA fraction in control, NAFL, T2D, and GSD1a. MUFA fraction was significantly lower in the GSD1a group compared to the
control group (p= 0.006). d PUFA fraction in control, NAFL, T2D, and GSD1a. Data are presented as mean with error bars showing the SEM. Different
letters indicate significant differences between groups (Kruskal–Wallis, p < 0.05 for IHL and PUFA, and one-way ANOVA, p < 0.05 for SFA and MUFA).
Bonferroni correction was used for post-hoc analyses.
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been shown that changes in DNL as determined by stable isotope
techniques correlate with changes in the fraction of palmitate in
VLDL-TG22. In line with this, DNL was positively correlated with
the hepatic SFA fraction in the current study. The hepatic MUFA
fraction was negatively correlated with DNL, whereas the hepatic
PUFA fraction did not correlate with DNL. From these results, it
follows that upon increased DNL, the production of SFA is not
necessarily accompanied by subsequent desaturation to MUFAs
in humans. This is in contrast to animal studies that indicate that
desaturation is upregulated in parallel to upregulation of lipo-
genic enzymes13. In line, Peter et al. showed that SCD1 mRNA
expression and C18:1/C18:0 ratio in TG and phospholipid frac-
tions in human liver were not increased in individuals with
NAFL23. Thus, handling of fatty acids originating from DNL by
the liver may be different in humans and animals. Increased
desaturation following lipogenesis is believed to be a rescue
mechanism to reduce the negative effects exerted by SFA13.
Further, we find higher hepatic SFA fraction in patients with
NAFL and T2DM compared to controls, which is in line with
earlier results, showing that the relative contribution of DNL-
derived FA to VLDL-TG was around 5–10% in healthy indivi-
duals in the fasted state, whereas their contribution increased to
around 20–25% in people with NAFL11,20,24,25. These results
suggest that the negative health effects that have been attributed
to increased rates of DNL may also be due to the high fraction of
SFA that result from DNL. Therefore, drug development targeting
DNL is promising26–28, although it is important to note that the
evidence in the present study is only associative and future
research will have to show whether decreasing the amount of SFA
has beneficial effects on metabolic health. Interestingly, however,
animal studies support this notion. In mice overexpressing
carbohydrate-responsive element-binding protein (ChREBP),
resulting in increased activity of SCD1 and higher MUFA frac-
tion, the increased MUFA fraction at the expense of SFA fraction
has been associated with increased IS, despite high amounts of
total hepatic fat content13. Furthermore, it has been shown
in vitro that specifically SFA negatively affect insulin signaling
and that desaturation of fatty acids can rescue these negative
effects13. In line with these animal and cell data, we here show
that the hepatic SFA fraction was negatively correlated and the
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Fig. 7 The relationship between liver fat composition and hepatic insulin sensitivity. The relationship between hepatic IS (EGP suppression) and a total
liver fat content, b SFA fraction, c MUFA fraction, d PUFA fraction, and e MUFA/SFA ratio in overweight and obese individuals (healthy with and without
NAFL in black and patients with T2D in red, n= 30 for total liver fat content and n= 29 for the fatty acid fractions and MUFA/SFA ratio). The correlation
coefficient is shown in the respective plots (Two-sided Spearman correlation). f EGP suppression in healthy overweight/obese without NAFL (controls,
n= 7), overweight/obese with NAFL (n= 14), and patients with T2D (n= 9). EGP suppression in patients with T2D was significantly lower compared to
controls (p= 0.002). Data are presented as mean with error bars showing the SEM. Different letters indicate significant differences between groups (one-
way ANOVA, p < 0.05). Bonferroni correction was used for post-hoc analyses.
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MUFA/SFA ratio positively correlated with hepatic IS in over-
weight and obese participants. Plasma (VLDL-)TG is often used
as a surrogate for hepatic TG. In addition, with sophisticated
centrifugation methods, saturation of plasma VLDL-TG can be
determined. Here we showed that saturation of hepatic lipids
correlated with the saturation in plasma VLDL-TG. Interestingly,
however, unlike the MRS determined SFA fraction, the SFA
fraction in VLDL-TG did not correlate with DNL. These results
indicate, that the SFA fraction determined by MRS is a better
measure of DNL compared to the SFA fraction in VLDL-TG, and
thus the use of our 1H-MRS approach provides extra valuable
information that could not be determined from plasma
VLDL-TG.
In summary, we developed an MR protocol that enabled us to
non-invasively quantify the fractions of hepatic SFA, MUFA, and
PUFA. Applying this 1H-MRS methodology, we here show that
the hepatic SFA fraction is positively associated with DNL, is
elevated in patients with NAFL and T2D, and negatively asso-
ciated with hepatic IS. These results indicate that hepatic lipid
composition, as determined by our 1H-MRS methodology, might
be used as measure of DNL and furthermore suggest that speci-
fically the hepatic SFA fraction may determine metabolic health.
Methods
Clinical study design. The study was conducted at Maastricht University Medical
Center, the Netherlands, between August 2017 and June 2018, and was approved
by the Medical Ethical Committee of Maastricht University Medical Center.
Research was performed in accordance with relevant ethical regulations regarding
human research participants. The study was registered at clinicaltrials.gov with
identifier NCT03211299.
Participants. All participants recruited for this study provided written informed
consent. Twenty-two healthy overweight/obese participants (BMI 27–35 kg/m2),
aged 45–70 years with a large range in liver fat content (0.9–38.4%) were recruited
for this study. Female study participants were postmenopausal. Exclusion criteria
were engagement in exercise for more than 2 h per week, unstable body weight
(weight loss or gain more than 3 kg in 3 months preceding enrollment), alcohol
consumption more than 2 units per day, smoking more than 5 cigarettes per day,
contra-indication for MRI, use of anti-coagulants, use of other medication known
to interfere with the outcome parameters, diabetes, or other active disease. Parti-
cipants participated in an MRS measurement, deuterated water measurement, and
two-step hyperinsulinemic-euglycemic clamp, including baseline subcutaneous
adipose tissue biopsy. All measurements took place within a time window of
6 weeks. Two days before each of the measurements, participants were instructed
to refrain from physical exercise and alcohol consumption. The evening before the
measurements, participants consumed a standardized high carbohydrate diner and
fasted overnight. For group comparisons, two patient groups were included in the
study: nine patients with type 2 diabetes and seven patients with GSD1a. Patients
with type 2 diabetes were aged 40–75 years, had a BMI between 25 and 38 kg/m2
and relatively well controlled type 2 diabetes: HbA1c < 9.5%. Patients had stable
dietary habits, were on treatment with oral medication only (Metformin, Tolbu-
tamide, or Gliclazide) and did not use other medication known to interfere with the
outcome parameters. Female patients were postmenopausal. Exclusion criteria were
engagement in exercise for more than 3 h per week, uncontrolled hypertension,
anemia, unstable body weight (weight loss or gain more than 5 kg in 3 months
preceding enrollment), alcohol, or drug abuse, being vegetarian or vegan, having
significant food allergies, contra-indication for MRI, use of anti-coagulants and
clinically relevant active disease. GSD1a patients were recruited aged 18 years and
older, clinically diagnosed with GSD1a and without contra-indication for MRI. In
vivo validation in adipose tissue was performed in a subgroup of the healthy
overweight/obese participants (n= 8). Reproducibility measurements in the liver
were performed in a separate group of individuals aged between 25–71 years and
BMI between 25.7–38.5 kg/m2 (n= 7).
Overview of specified outcomes. The primary outcome was lipid composition
(SFA fraction) as measured by MRS and rates of DNL as measured by incor-
poration of deuterated water. Secondary outcome was hepatic IS as determined by
suppression of hepatic glucose output during the low insulin phase in a two-step
hyperinsulinemic-euglycemic clamp.
Measurement of lipid content and lipid composition. In this study, the lipid
content and lipid composition (fraction of hepatic SFA, MUFA, and PUFA) were
determined by proton magnetic resonance spectroscopy (1H-MRS) (healthy
overweight/obese controls without NAFL: n= 7 for total liver fat content, n= 6 for
liver fat composition, healthy overweight/obese with NAFL: n= 15, patients with
type 2 diabetes: n= 9 and patients with GSD type 1a: n= 7). All 1H-MRS
experiments were performed on a 3T MR system (Achieva 3T-X Philips Health-
care, Best, Netherlands) by using a 32-channel sense cardiac/torso coil (Philips
Healthcare, Best, Netherlands). All spectra were obtained by using a STEAM
sequence29 with the following parameters; repetition time (TR) 4500 ms/echo time
(TE) 20 ms/mixing time (TM) 16 ms, spectral bandwidth 2000 Hz and data points
2048. For the in vivo hepatic lipid spectra VAPOR water suppression30 was applied
and an additional water reference scan was obtained. The number of averages was
16 for the phantom experiments and in adipose tissue and 128 for the in vivo
hepatic spectra. We used a voxel size of 30 × 30 × 30 mm for the hepatic and 15 ×
15 × 15mm for the adipose tissue measurements.
All obtained lipid spectra were post-processed in a home-written MATLAB
(MATLAB 2014b, The MathWorks, Inc., Natick, MA, USA) script in which, prior
to fitting, all spectra are individually corrected for phase and frequency shift.
Additionally, we performed eddy current correction for the individual lipid spectra.
Phasing, frequency alignment, and eddy current correction were all performed on
individual spectra before signal averaging. Bad quality spectra from in vivo (e.g.
due to motion) were removed automatically. For this, the linewidth, amplitude, and
frequency offset of the peaks in each individual spectrum were compared to the
average values of all spectra.
For the setup of the post-processing routine we used a four-step approach. First,
we acquired both 1H and 13C HR NMR spectra from five different oils (olive,
arachis, sunflower, safflower, and rice oil), by using a pulse-acquire sequence. The
lipid composition of the different oils was determined by integration of the peaks in
the methyl region in the 13C HR spectra. In the 1H HR spectra four different
regions were integrated, corresponding to the methyl protons (around 0.90 ppm),
the allylic protons (around 2.02 ppm), the alpha carbonyl group (around 2.20
ppm), and the diallylic protons (around 2.75 ppm) (Supplementary Fig. 1). The 1H
HR spectra were used to develop a basis set used by the developed fitting algorithm.
The lipid signal was described by 16 individual resonances (2 for the methyl group,
5 for the methylene group, 1 for the beta methyle-group, 2 for the allylic group, 2
for the alpha-carbonyl group, and 1 for the diallylic group). In this basis set, the
relative frequency shifts, the splitting patterns and the initial linewidths were
described.
In a second setup step, we acquired spectra from the different oils on our
clinical 3T scanner. Eddy current correction was applied based on an additional
water reference scan with an identical experimental setup. The oil spectra were
fitted with the developed Matlab algorithm. To this end, using the basis set from
the HR spectra, the time domain signal was simulated. The amplitudes and relative
frequency shifts of the individual peaks were updated iteratively. In each step the
difference between the simulated spectrum and the acquired spectrum was
minimized in the frequency domain. Next to these individual parameters, also the
Gaussian line broadening, the Lorentzian line broadening, the zero order phase, an
overall frequency shift and the baseline offset were automatically updated, affecting
all the peaks in an identical fashion. Essential for our approach, we furthermore
fixed the ratio of the methyl group and the alpha-carbonyl group (which overlaps
with the allylic group at 3T) to 0.6. Theoretically this factor should be 0.67, as the
methyl group contains three protons and the alpha-carbonyl group contains two
protons and both groups are present only once in every fatty acid. However, due to
TE-induced losses this factor will be affected. Therefore, this factor was determined
empirically. In a final fine-tuning step of the fitting routine, the zero-order phase
was accurately fitted by minimizing the residual in the spectrum in the methyl and
allylic+ alpha-carboxyl region specifically.
The signal amplitude ratio of the diallylic over the methyl peaks and the ratio of
the alpha-carbonyl+ allylic over the methyl peaks was determined in both the
phantom and the HR experiment, to empirically determine correction factors for
TE-induced signal in our STEAM recordings. These empirically determined
correction factors were then used for the measurements in adipose tissue and in the
liver to calculate the lipid composition using the following formulas:
%PUFA ¼ CA* 2
3
*
Sdiallylic
Smethyl
 
*100
%MUFA ¼ CB* 3
4
*
Salphacarb þ Sallylic
Smethyl
 2
3
 
*100
 
%PUFA
%SFA ¼ 100%PUFA%MUFA
with CA and CB the empirically determined correction factor for the PUFA and
MUFA calculation, respectively (CA= 0.83 and CB= 0.99; see also Supplementary
Table 1).
In a third step, the lipid composition in subcutaneous adipose tissue was
determined in vivo with 1H-MRS using the developed fitting routine and this was
compared to the ex vivo lipid composition as determined by mass spectrometry
analysis in adipose tissue biopsies, in eight participants. For the adipose tissue 1H-
MRS measurement, we applied a gradient cycled STEAM sequence, to correct for
eddy currents, as previously described31.
In a final validation step to determine reproducibility, we applied the developed
methodology in the liver of seven healthy individuals (BMI 30.6 ± 3.7 kg/m2; age
49 ± 17.2 year; 3 women), with a wide range of intrahepatic fat (2.1–19.6%). To this
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end, we performed the 1H-MRS acquisition and repeated this after replacement of
the subject on the table. The ICC was calculated for the lipid composition and total
lipid content as a measure to determine the reproducibility between two
consecutive measurements. Lipid content was calculated after T2 correction as ratio
of the CH3 peak relative to the unsuppressed water resonance, expressed as
percentage weight/weight.
Deuterated water measurement of DNL. A background blood sample was drawn
in the afternoon before intake of the deuterated water in 18 healthy overweight/
obese participants. Together with the evening meal, participants were given 2.86 g/
kg body weight deuterated water (70% 2H2O, Cambridge Isotope laboratories) in
two servings. A blood sample for DNL analysis was drawn at fasting in the
morning, 16 h after the first serving of deuterated water. The DNL was analyzed
from enrichment in VLDL-TG of deuterated water10,32. Two participants were
excluded from the analysis of DNL because of TG levels higher than 4 mmol/L,
influencing the reliability of the deuterated water measurement.
Body composition. Body mass and body volume were assessed using air-
displacement plethysmography (ADP) using the Bod Pod device (Cosmed, Italy,
Rome) according to the manufacturers instructions on the day of the
hyperinsulinemic-euglycemic clamp (healthy overweight/obese volunteers: n= 21,
patients with type 2 diabetes: n= 9)33. Thoracic gas volume was predicted based on
equations included in the Bod Pod software (version 4.2.0). From these data, body
fat percentage was calculated as described by Siri34.
Subcutaneous adipose tissue biopsy. In a subgroup of eight healthy overweight/
obese participants, a subcutaneous adipose tissue biopsy (~1 g) was collected 6–8
cm lateral from the umbilicus, under local anesthesia (1% lidocaine) by needle
biopsy before the start of the hyperinsulinemic-euglycemic clamp. Upon tissue
collection, the tissue was rinsed with sterile saline and visible blood vessels were
removed. Thereafter, the biopsy was snap-frozen in liquid nitrogen and stored at
80 °C for later lipid composition analyses.
Analysis of VLDL and adipose tissue triglycerides. Plasma samples used for
VLDL-TG analyses were taken around 16 pm before the intake of the deuterated
water. The VLDL fractions (20–50 µl) and adipose tissues (10–20mg) were
extracted using the BUME method35,36. The total lipid extracts were evaporated
under a stream of nitrogen and reconstituted in 250 µL chloroform/methanol [2:1].
Triglycerides were detected by direct infusion (shotgun) analysis on a QTRAP 5500
mass spectrometer (Sciex, Concord, Canada) equipped with a robotic nanoflow ion
source, TriVersa NanoMate (Advion BioSciences, Ithaca, NJ) according to previous
work37. More specifically, a fraction of the total lipid extract was diluted 1:100 (for
VLDL) and 1:100,000 (for adipose tissue) in chloroform:methanol [1:2] with 5mM
ammonium acetate and infused at 250 nl/min for 15min. The NanoMate was run
with a voltage of 1.2 kV and a gas pressure of 0.8 psi. The analysis was performed in
positive ion mode by neutral loss detection of 11 common acyl fragments formed
during collision-induced dissociation of the ammoniated triglycerides. The nano-
interface of the mass spectrometer was heated to 60 °C and the measurements was
made using a scan speed of 200 Da/s. The neutral loss scans were cycled and in total
50 cycles were acquired for each neutral loss scan (one neutral loss for each fatty
acid). The data was processed using the LipidView 1.2 software (Sciex, Concord,
Canada) and the most abundant signal intensities from the most commonly found
triglyceride species were used to calculate the abundance and composition of the
different triglycerides (Supplementary Tables 2 and 3). Quantification was made
using a one point calibration against glyceryl-d5-hexadecanoate (CDN isotopes,
Quebec, Canada), which was added to the infusion solvent.
Hyperinsulinemic-euglycemic clamp. A two-step hyperinsulinemic-euglycemic
clamp was performed to assess hepatic IS using the low-dose phase (10 mU/m2/
min) (healthy overweight/obese participants: n= 21). A primed continuous infu-
sion of D-[6,6-2 H2]glucose (0.04 mg/kg/min) was started to determine rates of
endogenous glucose production (EGP), glucose appearance (Ra), and glucose
disposal (Rd). After 180 min, participants were given infusion of low insulin (10
mU/m2 /min) for 3 h. During the last 30 min of the insulin infusion step, blood
samples were collected. Steele’s single pool non-steady-state equations were used to
calculate glucose Ra and Rd38. Volume of distribution was assumed to be 0.160 L/
kg for glucose. Hepatic IS was calculated as the percentage of EGP suppression
during the low-dose phase. In addition, hepatic IS was determined according to this
methodology in patients with type 2 diabetes (n= 9). Clamp parameters are shown
in Supplementary Table 4.
Statistical analysis. Results are expressed as mean ± SEM for group comparisons.
Population characteristics are expressed as mean ± SD. Continuous variables were
tested for normality. Two-sided Pearson correlation was performed to identify
correlations between variables. For non-normally distributed data two-sided
Spearman correlation was performed. Group comparisons were assessed by one-
way ANOVA. For non-normally distributed data Kruskal–Wallis analyses was
performed to compare groups. In case of significant group differences in the group
comparisons, post-hoc analyses were performed using Bonferroni correction to test
which groups were significantly different. A p-value < 0.05 was considered statis-
tically significant. Statistical analyses were performed using SPSS 23.0 for Mac OS.
Data availability
The source data underlying Figs. 1–7, Table 1 and Supplementary Table 4 are provided as
a Source Data file and are available from the corresponding author upon reasonable
request.
Code availability
Insights in the details of the code is available upon request.
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